SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
129 hedge funds and large institutions have $31.1M invested in SANGAMO THERAPEUTICS INC in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 28 closing their positions.
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 131 → 129 (-2)
7.71% less ownership
Funds ownership: 49.58% → 41.88% (-7.7%)
25% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 44
52% less call options, than puts
Call options by funds: $29K | Put options by funds: $60K
54% less capital invested
Capital invested by funds: $68.2M → $31.1M (-$37.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.49M |
| 2 |
Renaissance Technologies
New York
|
+$826K |
| 3 |
Millennium Management
New York
|
+$704K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$402K |
| 5 |
Goldman Sachs
New York
|
+$379K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.63M |
| 2 |
AC
Armistice Capital
New York
|
-$1.57M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.21M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.03M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$839K |
SGMO Hedge Fund Activity: Q2 2024 in Review
129 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2024, worth a combined $31.1M — down 54% from $68.2M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of SGMO and 26 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 33 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $1.49M. The largest seller was BlackRock, cutting an estimated $4.63M.
- 129 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2024, down from 131 in Q1 2024.
- Funds reported $31.1M of SANGAMO THERAPEUTICS INC stock for Q2 2024, down 54% quarter-over-quarter.
- 26 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2024 and 28 closed out, a net change of -2 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q2 2024 was Jacobs Levy Equity Management, an estimated $1.49M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q2 2024 was BlackRock, an estimated $4.63M sold.
Based on aggregated 13F filings for Q2 2024.